# A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs

> **NCT02308163** · PHASE3 · COMPLETED · sponsor: **Astellas Pharma Inc** · enrollment: 509 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Peficitinib
- **DRUG:** Placebo
- **BIOLOGICAL:** Etanercept

## Key facts

- **NCT ID:** NCT02308163
- **Lead sponsor:** Astellas Pharma Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-08
- **Primary completion:** 2017-01-23
- **Final completion:** 2017-11-22
- **Target enrollment:** 509 (ACTUAL)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02308163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02308163, "A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02308163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*